Hematologic Malignancies

Hematologic malignancies are cancers that arise from the blood, bone marrow, and lymph nodes—the tissues where blood cells are made and where the immune system's cells live and travel.

10 frameworks, from 1870 to today · Oncology · Medicine & Health

still a working view ended · each leads to its entry below

Overview

Hematologic malignancies are cancers that arise from the blood, bone marrow, and lymph nodes—the tissues where blood cells are made and where the immune system's cells live and travel12. The three great families are the leukemias (cancerous blood cells spreading through marrow and blood), the lymphomas (cancers of lymphocytes that usually form masses in lymph nodes or other organs), and the plasma-cell cancers, of which multiple myeloma is the most important. The field matters because these diseases are at once among the most systemic of cancers—there is no tumor to cut out, since malignant cells circulate and colonize the whole marrow—and among the most instructive: blood and marrow are easy to sample, and the cells can be watched, counted, and manipulated in ways solid tumors never allowed. Much of what oncology now knows about cancer biology and about curing disseminated cancer was learned here first.

Blood counts, cell staining, and the birth of a morphological science

Before the microscope told anyone what blood contained, leukemia was recognized only as a strange, fatal wasting. The pivotal shift came in the mid-nineteenth century, when physicians who examined the blood of sick patients saw something unexpected: enormous numbers of white cells. The pathologists Rudolf Virchow in Berlin and John Bennett in Edinburgh, working independently around 1845, described such cases, and Virchow gave the condition its name—leukemia, "white blood"—and framed it as a disease of the blood-forming tissue itself rather than a mere excess of cells. The idea that the marrow was the parent organ of the blood was established later in the century, notably through the observations of Ernst Neumann and others, and it turned leukemia from a curiosity into a disorder with a seat in the body.

For decades after that, the discipline was essentially morphological: diagnosis and classification rested on what cells looked like under a stain. Paul Ehrlich's aniline dyes in the 1870s and 1880s made it possible to distinguish cell lineages by their granules and nuclear shapes, and the great hematologists of the early twentieth century built a taxonomy of cell types—myeloid and lymphoid, acute and chronic—that still underpins the names of the diseases. The practical consequence was a vocabulary and a set of diagnostic categories that clinicians could use to predict course and choose treatment. It was also a limit: two leukemias that looked alike under the microscope could behave very differently, and the morphology alone could not say why.

Radiation, the first cures, and the arrival of chemotherapy

The first genuinely effective therapy came from physics. Within a few years of Röntgen's discovery of X-rays, physicians found that radiation could shrink leukemic infiltrates and enlarged lymph nodes. By the early twentieth century, radiation therapy was the mainstay for lymphoma, and for a time Hodgkin disease—then defined only by its distinctive lymph-node pattern and the Reed–Sternberg cells seen on biopsy—became one of the few cancers that radiation could sometimes cure. The limitation was obvious: radiation treats a field, but leukemia and advanced lymphoma are everywhere, and systemic disease could not be irradiated.

The answer was drugs that travel through the body. The decisive wartime observation was that nitrogen mustard, a chemical warfare agent, depleted the bone marrow and lymphoid tissue of exposed people; from this, investigators including Louis Goodman and Alfred Gilman in the 1940s tested mustard compounds in lymphoma patients and saw tumors shrink. The broader program came from Sidney Farber's work in the late 1940s on childhood acute lymphoblastic leukemia: folate antagonists such as aminopterin produced temporary remissions in children who had been expected to die within weeks. The lesson of these early trials was double-edged—remissions were real, and remissions were temporary, because resistant cells survived and regrew.

Combination chemotherapy and the idea of cure

That problem—resistance and relapse—produced the field's central therapeutic idea. If a drug kills most cells but leaves a resistant minority, then using several drugs with different mechanisms at once should reduce the chance that any cell escapes all of them. The principle was worked out empirically in childhood leukemia by investigators including Emil Freireich, Emil Frei, and James Holland at the National Cancer Institute and its cooperating groups in the 1950s and 1960s: by combining drugs such as methotrexate, mercaptopurine, vincristine, and prednisone, and later adding prophylaxis against leukemic cells hiding in the central nervous system, they turned a disease that had killed nearly every child into one with a substantial proportion of long-term survivors by the 1970s. The same logic, applied to Hodgkin disease by Vincent DeVita and colleagues at the NCI, produced combination regimens that cured a majority of patients with advanced disease—the first demonstration that a disseminated cancer could routinely be cured with drugs. The randomized controlled trial, developed as the instrument for judging such regimens against alternatives, became inseparable from the field's progress.

The stem-cell model and the marrow as a replaceable organ

Parallel to the drug work, a biological question drove the field: where do blood cells come from, and what cell goes wrong in leukemia? In the early 1960s, James Till and Ernest McCulloch showed that single cells from mouse marrow could form colonies in the spleens of irradiated animals—direct evidence of a self-renewing progenitor that could rebuild the whole blood system. This hematopoietic stem-cell model did two things. It explained why marrow failure followed radiation and chemotherapy (the stem cell pool was being killed), and it suggested a therapeutic possibility: if the marrow could be destroyed and then replaced, aggressive treatment that would otherwise be lethal to the patient might become survivable.

That possibility became hematopoietic stem-cell transplantation. After early attempts in the 1950s, E. Donnall Thomas and colleagues in Seattle demonstrated in the late 1960s and 1970s that marrow from a matched sibling donor could rescue patients after high-dose irradiation and chemotherapy, and that some patients with leukemia were cured. The hurdles were severe and instructive: graft-versus-host disease, in which donor immune cells attack the patient; rejection; infection during the months before the new marrow engrafts; and the difficulty of finding a matched donor. Each was attacked in turn—through better tissue typing, immunosuppressive drugs, and the recognition of the graft-versus-leukemia effect, in which donor cells attack residual cancer cells. The result was a procedure that converted a fatal disease of the marrow into something a patient could survive, and that remains one of the clearest proofs that a cancer's microenvironment and immune context can be part of its cure.

Cytogenetics, molecular biology, and the disease paradigm

Morphology and clinical course classified the diseases; the next revolution explained them. The key observation was chromosomal: in 1960, Peter Nowell and David Hungerford in Philadelphia described a small abnormal chromosome—the "Philadelphia chromosome"—in the cells of patients with chronic myeloid leukemia3. Its molecular meaning came later, when the translocation was shown to fuse the BCR and ABL genes and produce an abnormal, constitutively active protein kinase that drives the malignant cell3. The result was not just a mechanism but a new kind of disease definition: an entity specified by a molecular lesion rather than by appearance.

This molecular and cytogenetic paradigm spread across the field. In the 1970s and after, improved chromosome banding, then molecular probes, then gene sequencing exposed a landscape of translocations, mutations, and gene fusions that divided morphologically similar leukemias and lymphomas into biologically distinct diseases—some with good prognosis, some with bad, some vulnerable to a particular drug. The lymphoma taxonomies were rebuilt around this: what had been a tangle of overlapping names gave way to entity-based classifications (the Working Formulation of 1982, then the Revised European–American Lymphoma classification of 1994 and the World Health Organization systems) that defined each disease by a combination of morphology, immunophenotype, genetics, and clinical features. The same repositioning occurred in leukemia classification and, through the work of investigators including Alfred Knudson's two-hit reasoning on retinoblastoma and the later myeloma literature, in the plasma-cell diseases. Diagnosis ceased to be a matter of recognizing a picture and became a matter of identifying a lesion.

Targeted therapy and the antibody

The Philadelphia chromosome pointed directly at a treatment. If a single abnormal kinase drives the disease, a drug that inhibits that kinase should work—and in the late 1990s imatinib, developed by Brian Druker and colleagues with the pharmaceutical company Novartis, did exactly that for chronic myeloid leukemia, producing high rates of durable remission in a disease that had previously been managed only for a time. This was the proof of concept for targeted therapy in cancer: a rationally designed small molecule aimed at the specific lesion that defines the disease. It also taught a cautionary lesson, since resistance mutations in the kinase emerged, requiring second-generation inhibitors—an arms race now built into the design of targeted drugs.

A parallel line of attack came from immunology. The idea of using antibodies to recognize molecules on the surface of cancer cells was made practical by the hybridoma method of Georges Köhler and César Milstein in 1975, which allowed unlimited production of a single antibody4. The first therapeutic successes were in lymphoma: rituximab, an antibody against the B-cell marker CD20, was approved in the late 1990s and made a measurable difference in survival when added to combination chemotherapy in B-cell lymphomas. Antibody-drug conjugates, which attach a cytotoxic drug to an antibody so it is delivered selectively, extended the idea. In myeloma, immunomodulatory drugs and then antibodies against targets such as CD38 and SLAMF7 reshaped treatment and turned a once rapidly fatal disease into a chronic, manageable one for many patients.

Engineered cells and bispecific antibodies

The most recent turn takes the immune system from a passive ally to an engineered weapon. Chimeric antigen receptor T cells—the patient's own T cells, genetically modified to carry a receptor that recognizes a cancer surface marker and to activate when it does—were developed in the laboratory through the 1990s and 2000s, and proved dramatically effective in some relapsed B-cell leukemias and lymphomas, leading to approved therapies by the late 2010s. Bispecific antibodies, engineered to bind a tumor marker with one arm and a T cell with the other, bring the same logic to an off-the-shelf drug. These treatments are powerful and dangerous in equal measure—cytokine release syndrome and neurological toxicity are real hazards—and they have made clear that the field's therapies can now be cells as much as chemicals.

The present

Hematologic malignancy today is a field defined by molecular classification and by a layered armamentarium: combination chemotherapy for the leukemias and aggressive lymphomas, targeted inhibitors for lesions such as BCR-ABL and others, monoclonal antibodies and antibody-drug conjugates, transplant for selected high-risk patients, and engineered cellular and bispecific immunotherapies for relapsed disease. The open questions are the ones the history has been circling: why some patients' cancers become resistant; how to predict who will benefit from transplant or from cellular therapy; how to make these treatments safer and more widely available; and whether the deep molecular understanding that now defines the diseases can be converted into cures for the ones that remain stubborn. The blood and marrow, sampled and manipulated more easily than any other tissue, will likely keep providing the answers.

References

  1. Tumors of the hematopoietic and lymphoid tissues, Wikipedia
  2. Leukemia, Wikipedia
  3. Philadelphia chromosome (History, introduction), Wikipedia
  4. Monoclonal antibody (History), Wikipedia

The frameworks of Hematologic Malignancies

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 1870-1980

    Morphological hematopathology

    What do blood and marrow cells look like in disease?

    Fly to its tower in Nousfarer

  2. 1900-1970
  3. 1950-Present
  4. 1955-Present
  5. 1960-Present

    Cytogenetic and molecular disease paradigm

    What molecular lesions define each blood cancer?

    Fly to its tower in Nousfarer

  6. 1961-Present
  7. 1982-Present

    Lymphoma entity-based taxonomy

    How should lymphomas be classified into distinct diseases?

    Fly to its tower in Nousfarer

  8. 1997-Present

    Monoclonal antibody therapy

    Can antibodies selectively kill cancer cells?

    Fly to its tower in Nousfarer

  9. 1998-Present

    Targeted small-molecule therapy

    Can a drug target the specific lesion driving a cancer?

    Fly to its tower in Nousfarer

  10. 2017-Present

    Engineered cellular and bispecific immunotherapy

    Can the immune system be engineered to cure blood cancers?

    Fly to its tower in Nousfarer

How the ideas connect

Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.

Morphological hematopathologyRadiation therapy of lymphoid diseaseHematopoietic stem-cell modelCombination chemotherapy and the cure…Cytogenetic and molecular disease par…Hematopoietic stem cell transplantati…Lymphoma entity-based taxonomyMonoclonal antibody therapyTargeted small-molecule therapyEngineered cellular and bispecific im…

Beyond the field

Where Hematologic Malignancies's ideas came from in other fields, and what they led to there: the strongest 12 of 42 links.

A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Hematologic Malignancies is a planet in Nousfarer

Its city has a tower for each of these 10 frameworks. Land, walk in, and climb one concept at a time.

Land on Hematologic Malignancies

Related fields

Fields its ideas are linked to

More in Oncology

See where Hematologic Malignancies sits on the Map of Human Knowledge